Sugary Soft Drink Consumption May Increase Risk of Developing Pancreatic Cancer(2/11/2010) Researchers affiliated with the Singapore Chinese Health Study have reported that individuals who consumed two or more sugary soft drinks per week experienced a statistically significant increased risk of pancreatic cancer when compared with individuals who did not consume soft drinks. The details of this study appeared in the February, 2010 issue of Cancer Epidemiology, Biomarkers, and Prevention.
Risk of Pancreatic Cancer in Families with Lynch Syndrome Defined(11/3/2009) Researchers from several U.S. medical centers have reported that patients with Lynch syndrome have an 8.6-fold increase in the risk of pancreatic cancer compared with the general population. The details of this study appeared in the October 28, 2009 issue of the Journal of the American Medical Association.
Smoking Increases Risk of Pancreatic Cancer(8/26/2009) Researchers from the National Cancer Institute have reported that smoking increases the risk of developing pancreatic cancer and that smoking cessation lowers this risk to baseline in 15 years. The details of this study appeared in the August 15, 2009 issue of the American Journal of Epidemiology.
Study Confirms Increased Risk of Pancreatic Cancer in A, B, or AB Individuals(8/7/2009) Researchers involved in a multicenter international trial have reported that individuals with the gene variant that results in A, B, or AB blood types appear to have a higher risk of developing pancreatic cancer than individuals with the gene variant that results in blood type O. These results were published early online in Nature Genetics on August 4, 2009.
PAM4 Enzyme May Help Detect Early-stage Pancreatic Cancer(2/25/2010) Researchers from Garden State Cancer Center, the Johns Hopkins Medical Institutions, and New York University Medical Center have reported that an enzyme, PAM4, may be detected by serum enzyme immunoassay (EIA) in patients with early-stage pancreatic cancer. The details of this study were presented at the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in late January.
Tarceva® Evaluated for Treatment of Pancreatic Cancer(2/24/2010) Several studies evaluating Tarceva® (erlotinib) for the treatment of pancreatic cancer were presented at the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (GCS) in January.
Adjuvant Chemoradiotherapy May Improve Survival of Patients with Pancreatic Cancer(2/12/2010) Researchers from the University of Miami have reported that adjuvant chemoradiotherapy, treatment in a high-volume hospital, and/or treatment in a teaching hospital were independent predictors of survival in patients treated with surgical resection for pancreatic cancer. The details of this study were published in the January, 2010 issue of the Archives of Surgery.
Sutent® Improves Progression-free Survival in Patients with Well Differentiated Pancreatic Islet Cell Tumors(9/29/2009) Researchers involved in an international randomized trial have reported that Sutent® (sunitinib) prolongs progression-free survival (PFS) in patients with progressive well differentiated pancreatic islet cell tumors with an acceptable toxicity profile. The details of this study were presented at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.
Afinitor® and Temodar®: An Active Regimen for Pancreatic Neuroendocrine Tumors(3/1/2010) Researchers from Massachusetts General Hospital have reported that the combination of Afinitor® (everolimus) and Temodar® (temozolomide) is active for the treatment of patients with advanced pancreatic neuroendocrine tumors (NET). The details of this Phase I/II study were presented at the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (GCS).
Tarceva® Evaluated for Treatment of Pancreatic Cancer(2/24/2010) Several studies evaluating Tarceva® (erlotinib) for the treatment of pancreatic cancer were presented at the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (GCS) in January.
Addition of Xeloda® to Gemzar® Improves Outcomes in Pancreatic Cancer(11/2/2009) Researchers affiliated with the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG) have reported that the addition of Xeloda® (capecitabine) to Gemzar® (gemcitabine) improves outcomes of patients with advanced or metastatic pancreatic cancer. The details of this study appeared early online October 26, 2009 in the Journal of Clinical Oncology.
Sutent® Improves Progression-free Survival in Patients with Well Differentiated Pancreatic Islet Cell Tumors(9/29/2009) Researchers involved in an international randomized trial have reported that Sutent® (sunitinib) prolongs progression-free survival (PFS) in patients with progressive well differentiated pancreatic islet cell tumors with an acceptable toxicity profile. The details of this study were presented at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.
Chemotherapy Better than Alternative Medicine Approach for Inoperable Pancreatic Cancer(9/15/2009) Researchers from Columbia University have reported that patients receiving Gemzar® (gemcitabine)-based chemotherapy for inoperable pancreatic cancer have a longer survival and better quality of life than those receiving an alternative medicine approach consisting of enzyme therapy, nutritional supplements, detoxification, and an organic diet. These results were published early online in the Journal of Clinical Oncologyon August 17, 2009.
Tarceva® Evaluated for Treatment of Pancreatic Cancer(2/24/2010) Several studies evaluating Tarceva® (erlotinib) for the treatment of pancreatic cancer were presented at the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (GCS) in January.
Pancreatic Cancer Care Is Inconsistent(7/23/2009) Researchers affiliated with the Cancer Programs, American College of Surgeons have reported that the quality of care for patients with pancreatic cancer varies considerably among hospitals in the United States. The details of this study appeared in June 16, 2009 issue of the Journal of the National Cancer Institute.
Normalization of N-telopeptide Associated with Improved Survival from Bone Metastasis Treated with Bisphosphonates(6/25/2008) Researchers involved in a multicenter international trial have reported that normalization of N-telopeptide of type I collagen (NTX) levels is associated with skeletal-related events and survival among patients with bone metastases from solid tumors treated with Zometa® (zoledronic acid) or Aredia® (pamidronate). These results were published in the July 1, 2008 issue of Cancer.
Different Chemotherapy Combinations Effective in Pancreatic Cancer(11/16/2007) A multi-center randomized trial comparing three different palliative chemotherapy regimens for patients with advanced pancreatic cancer has found that all three regimens were equally effective but with differing side effects. The details of this study appeared in an early on-line publication in the Annals of Oncology on October 24, 2007.
Gemzar® Plus Second Chemotherapy Agent Provides Small Survival Benefit in Advanced Pancreatic Cancer(10/8/2007) Researchers from France have reported that the combination of Gemzar® (gemcitabine) with a second chemotherapy agent provides a small but significant improvement in survival compared with Gemzar only in the treatment of metastatic pancreatic cancer. The details of this metaanalysis were reported in the October, 2007 issue of Drugs and Aging.
Patient Home
